Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

Stock Information for Scholar Rock Holding Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Scholar Rock Holding Corporation

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock
Scholar Rock Announces Proposed Public Offering of Common Stock
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.